Skip to main navigation

AnaptysBio

Investor Relations

  • About
    • Overview
    • Strategy
    • Senior Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Contact
  • Science
    • Immune Cell Modulation
    • Publications
  • Pipeline
    • Overview
    • Rosnilimab
    • ANB032
    • ANB033
    • ANB101
    • Imsidolimab
    • Partnerships
  • Investors / News
    • Overview
    • News
    • Events
    • Presentations
    • Governance
    • Stock Information
    • Analyst Coverage
    • SEC Filings
    • Investor FAQs
    • Contact
  • Careers
    • Overview
    • Job Openings
    • Core Values
    • Total Reward Program Highlights
    • AnaptysBio Culture
  • Contact
Toggle

SEC Filing Details

SEC Filing Details

Document Details

Form
10-Q
Filing Date
Aug 7, 2023
Document Date
Jun 30, 2023
Form Description
Quarterly report which provides a continuing view of a company's financial position
Filing Group
Quarterly Filings
Company
AnaptysBio, Inc.
Issuer
ANAPTYSBIO, INC

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS

XBRL

XBRL Viewer
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
XML - XBRL INSTANCE DOCUMENT

Tools

  • Print

    Print

  • Email

    Email

  • RSS Feeds

    RSS Feeds

  • Email Alerts

    Email Alerts

  • Investor Contact

    Investor Contact

  • Document Request

    Document Request

 

AnaptysBio, Inc.

10770 Wateridge Circle
Suite 210
San Diego, CA 92121-5801
(858) 362-6295 (ph)
(858) 362-6296 (fax)
info@anaptysbio.com
  • clear
  • clear

Quick Links

  • About
  • Science
  • Investors / News
  • Careers
  • Contact

Pipeline

  • Rosnilimab
  • ANB032
  • ANB033
  • Imsidolimab
  • Partnerships
© 2023 AnaptysBio, Inc. All Rights Reserved.
Privacy Policy  |  Terms Of Use